Progress in Warfarin Dosing | GenomeWeb

Progress in Warfarin Dosing


Recently, British and Swedish researchers published what they call the first genome-wide association study for warfarin dosing with sufficient power to detect variants of modest effect. In 1,053 Swedish patients, they confirmed the well-known VKORC1 and CYP2C9 SNPs and uncovered a third SNP, CYP4F2, which they then corroborated in an additional cohort of 588 Swedish patients. GT's Ciara Curtin caught up with the Sanger Institute's Panos Deloukas to discuss the implications of his study and what future studies may determine. The team's paper was published in PLoS Genetics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.